Book contents
- Treatment-Related StrokeIncluding Iatrogenic and In-hospital Strokes
- Treatment-Related Stroke
- Copyright page
- Dedication
- Contents
- Contributors
- Preface
- Section I Iatrogenic ischemic strokes: peri- and postoperative strokes
- Section II Iatrogenic ischemic strokes: stroke after endovascular procedures
- Section III Iatrogenic ischemic strokes: other causes
- Section IV Iatrogenic hemorrhagic strokes: thrombolysis-related hemorrhagic strokes
- Section V Iatrogenic hemorrhagic strokes: intracranial bleeding
- Section VI Iatrogenic hemorrhagic strokes: anticoagulation-related intracranial hemorrhage
- Section VII Other uncommon causes of iatrogenic stroke
- Section VIII Cerebral venous thrombosis
- Section IX Medication reversal and restarting in patients with iatrogenic strokes
- Index
- References
Section VII - Other uncommon causes of iatrogenic stroke
Published online by Cambridge University Press: 20 October 2016
Book contents
- Treatment-Related StrokeIncluding Iatrogenic and In-hospital Strokes
- Treatment-Related Stroke
- Copyright page
- Dedication
- Contents
- Contributors
- Preface
- Section I Iatrogenic ischemic strokes: peri- and postoperative strokes
- Section II Iatrogenic ischemic strokes: stroke after endovascular procedures
- Section III Iatrogenic ischemic strokes: other causes
- Section IV Iatrogenic hemorrhagic strokes: thrombolysis-related hemorrhagic strokes
- Section V Iatrogenic hemorrhagic strokes: intracranial bleeding
- Section VI Iatrogenic hemorrhagic strokes: anticoagulation-related intracranial hemorrhage
- Section VII Other uncommon causes of iatrogenic stroke
- Section VIII Cerebral venous thrombosis
- Section IX Medication reversal and restarting in patients with iatrogenic strokes
- Index
- References
- Type
- Chapter
- Information
- Treatment-Related StrokeIncluding Iatrogenic and In-Hospital Strokes, pp. 203 - 240Publisher: Cambridge University PressPrint publication year: 2016
References
References
George, M G, Tong, X, Kuklina, E V, Labarthe, D R. Trends in stroke hospitalizations and associated risk factors among children and young adults, 1995–2008. Ann Neurol. 2011; 70:713–21.
Dias, M, Sekhar, L. Intracranial hemorrhage from aneurysms and arteriovenous malformations during pregnancy and the puerperium. Neurosurgery. 1990; 27:855–65.
James, A, Bushnell, C D, Jaminson, M G, Myers, E R. Incidence and risk factors for stroke in pregnancy and puerperium. Obstet Gynecol. 2005; 106:509–16.
Say, L, Souza, J P, Pattinson, R C; WHO working group on Maternal Mortality and Morbidity classifications. Maternal near miss: Towards a standard tool for monitoring quality of maternal health care. Best Pract Res Clin Obstet Gynaecol. 2009; 23:287–96.
Kuklina, E V, Tong, X, Bansil, P, George, M G, Callaghan, W M. Trends in pregnancy hospitalizations that included a stroke in the United States from 1994 to 2007: Reasons for concern? Stroke. 2011; 42:2564–70.
Sharshar, T, Lamy, C, Mas, J L, The Stroke in Pregnancy Group. Incidence and causes of stroke associated with pregnancy and puerperium: a study in public hospitals of Ile de France. Stroke. 1995; 26:930–6.
Liang, C C, Chang, S D, Lai, S L, et al. Stroke complicating pregnancy and the puerperium. Eur J Neurol. 2006; 13:1256–60.
Wiebers, D O, Whisnant, J P. The incidence of stroke among pregnant women in Rochester, Minn, 1955 through 1979. JAMA. 1985; 254:3055–7.
Awada, A, al Rajeh, S, Duarte, R, Russell, N. Stroke and pregnancy. Int J Gynaecol Obstet. 1995; 48:157–61.
Kittner, S J, Stern, B J, Feeser, B R, et al. Pregnancy and the risk of stroke. N Engl J Med. 1996; 335:768–74.
Witlin, A G, Friedman, S A, Egerman, R S, Frangieh, A Y, Sibai, B M. Cerebrovascular disorders complicating pregnancy: beyond eclampsia. Am J Obstet Gynecol. 1997; 176:1139–45.
Jaigobin, C, Silver, F L. Stroke and pregnancy. Stroke. 2000; 31:2948–51.
Skidmore, F M, Williams, L S, Fradkin, K D, Alonso, R J, Biller, J. Presentation, etiology and outcome of stroke in pregnancy and puerperium. J Stroke Cerebrovasc Dis. 2001; 10:1–10.
Jeng, J S, Tang, S C, Yip, P K. Incidence and etiologies of stroke during pregnancy and puerperium as evidenced in Taiwanese women. Cerebrovasc Dis. 2004; 18:290–5.
Ros, H S, Lichtestein, P, Bellocco, R, Petersson, R, Cnattingius, S. Increased risks of circulatory diseases in late pregnancy and puerperium. Epidemiology. 2001; 12:456–60.
Hunter, S, Robson, S C. Adaptation of the maternal heart in pregnancy. Brit Heart J. 1992; 68:540–3.
Bremme, K A. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol. 2003; 16:153–68.
ACOG Committee on Obstetric Practice. ACOG Committee Opinion Number 299, September 2004. Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol. 2004; 104:647–51.
Kanal, E, Borgstede, J P, Barkovich, A J, et al. American College of Radiology. American College of Radiology White Paper on MR Safety. Am J Roentgenol. 2002; 178:1335–47.
Stoddard, M F, Longaker, R A, Vuocolo, L M, Dawkins, P R. Trans-esophageal echocardiography in the pregnant patient. Am Heart J. 1992; 124:785–7.
Lanska, D J, Kryscio, R J. Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke. 2000; 31:1274–82.
Ros, H S, Lichtenstein, P, Bellocco, R, Petersson, G, Cnattingius, S. Pulmonary embolism and stroke in relation to pregnancy: How can high-risk women be identified? Am J Obstet Gynecol. 2002; 186:198–203.
Clark, S L, Hankins, G D, Dudley, D A, Dildy, G A, Porter, T F. Amniotic fluid embolism: Analysis of the national registry. Am J Obstet Gynecol. 1995; 172:1158–69.
Sibai, B, Dekker, G, Kupferminc, M. Pre-eclampsia. Lancet. 2005; 365:785–99.
Moodley, J, Kalane, G. A review of the management of eclampsia: practical issues. Hypertens Pregnancy. 2006; 25:47–62.
Roberts, J M, Cooper, D W. Pathogenesis and genetics of pre-eclampsia. Lancet. 2001; 357:53–6.
Elkayam, U, Akhter, M W, Singh, H, et al. Pregnancy-associated cardiomyopathy: Clinical characteristics and a comparison between early and late presentation. Circulation. 2005; 111:2050–5.
Abboud, J, Murad, Y, Chen-Scarabelli, C, Saravolatz, L, Scarabelli, T. Peripartum cardiomyopathy: a comprehensive review. Int J Cardiol. 2007; 118:295–303.
Pearson, G D, Veille, J C, Rahimtoola, S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000; 283:1183–8.
Mas, J L, Lamy, C. Stroke in pregnancy and the puerperium. J Neurol. 1998; 245:305–13.
Fugate, J E, Ameriso, S F, Ortiz, G, et al. Variable presentations of postpartum angiopathy. Stroke. 2012; 43:670–6.
Huang, C Y, Chen, C A, Hsieh, C Y, Cheng, W F. Intracerebral hemorrhage as initial presentation of gestational choriocarcinoma: A case report and literature review. Int J Gynecol Cancer. 2007; 17:1166–71.
Lanska, D J, Kryscio, R J. Peripartum stroke and intracranial venous thrombosis in the National Hospital Discharge Survey. Obstet Gynecol. 1997; 89:413–18.
Lanska, D J, Kryscio, R J. Stroke and intracranial venous thrombosis during pregnancy and puerperium. Neurology. 1998; 51:1622–8.
Cantu, C, Barinagarrementaria, F. Cerebral venous thrombosis associated with pregnancy and the puerperium: a review of 67 cases. Stroke. 1993; 24:1880–4.
Furie, K L, Kasner, S E, Adams, R J, et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42:227–76.
Bates, S, Greer, I, Pabinger, I, Sofaer, S, Hirsch, J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy. Chest. 2008; 133:844S–886S.
Kozer, E, Nikfar, S, Costei, A, et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol. 2002; 187:1623–30.
Coomarasamy, A, Honest, H, Papaioannou, S, Gee, H, Khan, K S. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003; 101:1319–32.
Greer, I A, Nelson-Piercy, C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005; 106:401–7.
Leonhardt, G, Gaul, C, Nietsch, H H, Buerke, M, Schleussner, E. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis. 2006; 21:271–6.
Dapprich, M, Boessenecker, W. Fibrinolysis with alteplase in a pregnant woman with stroke. Cerebrovasc Dis. 2002; 13:290.
Elford, K, Leader, A, Wee, R, Stys, P K. Stroke in ovarian hyperstimulation syndrome in early pregnancy treated with intra-arterial rt-PA. Neurology. 2002; 59:1270–2.
Johnson, D M, Kramer, D C, Cohen, E, et al. Thrombolytic therapy for acute stroke in late pregnancy with intra-arterial recombinant tissue plasminogen activator. Stroke. 2005; 36:e53–e55.
Wiese, K M, Talkad, A, Mathews, M, Wang, D. Intravenous recombinant tissue plasminogen activator in a pregnant woman with cardioembolic stroke. Stroke. 2006; 37:2168–9.
Murugappan, A, Coplin, W M, Al-Sadat, A N, et al. Thrombolytic therapy of acute ischemic stroke during pregnancy. Neurology. 2006; 66:768–70.
Li, Y, Margraf, J, Kluck, B, Jenny, D, Castaldo, J. Thrombolytic therapy for ischemic stroke secondary to paradoxical embolism in pregnancy: A case report and literature review. Neurologist. 2012; 18:44–8.
Mantoan Ritter, L, Schüler, A, Gangopadhyay, R, et al. Successful thrombolysis of stroke with intravenous alteplase in the third trimester of pregnancy. J Neurol. 2014; 261:632–4.
Méndez, J C, Masjuán, J, García, N, de Leciñana, M. Successful intra-arterial thrombolysis for acute ischemic stroke in the immediate postpartum period: Case report. Cardiovasc Intervent Radiol. 2008; 31:193–5.
Rønning, O M, Dahl, A, Bakke, S J, Hussain, A I, Deilkås, E. Stroke in the puerperium treated with intra-arterial rt-PA. J Neurol Neurosurg Psychiatry. 2010; 81:585–6.
Barrett, J M, Van Hooydonk, J E, Boehm, F H. Pregnancy-related rupture of arterial aneurysms. Obstet Gynecol Surv. 1982; 37:557–66.
Marshman, L A, Aspoas, A R, Rai, M S, Chawda, S J. The implications of ISAT and ISUIA for the management of cerebral aneurysms during pregnancy. Neurosurg Rev. 2007; 30:177–80.
Meyers, P M, Halbach, V V, Malek, A M, et al. Endovascular treatment of cerebral artery aneurysms during pregnancy: Report of three cases. Am J Neuroradiol. 2000; 21:1306–11.
Piotin, M, Filho, C B A, Kothimbakam, R, Moret, J. Endovascular treatment of acutely ruptured intracranial aneurysm in pregnancy. Am J Obstet Gynecol. 2001; 185:1261–2.
Marshman, L A G, Aspoas, A R, Rai, M S. Endovascular treatment of ruptured intracranial aneurysms during pregnancy: Letter. Arch Gynecol Obstet. 2005; 272:93.
Bateman, B, Schumacher, H, Bushnell, C D, et al. Intracerebral hemorrhage in pregnancy. Frequency, risk factors, and outcome. Neurology. 2006; 67:424–9.
Sawin, P. Spontaneous subarachnoid hemorrhage in pregnancy and the puerperium. In Loftus, C, ed. Neurological Aspects of Pregnancy. Park Ridge, IL: American Association of Neurological Surgeons; 1996: 85–99.
Roman, H, Descargues, G, Lopes, M, et al. Subarachnoid hemorrhage due to cerebral aneurysmal rupture during pregnancy. Acta Obstet Gynecol Scand. 2004; 83:330–4.
Wright, V C, Schieve, L A, Reynolds, M A, Jeng, G. Assisted reproductive technology surveillance in United States, 2002. MMWR. 2005; 54:1–24.
Whelan, J G, Vlahos, N F. The ovarian hyperstimulation syndrome. Fertil Steril. 2000; 73:893–6.
Chan, W S, Dixon, M E. The “ART” of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res. 2008; 121:713–26.
Kodama, H, Fukuda, J, Karube, H, et al. Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome. Fertil Steril. 1996; 66:417–24.
References
Watson, T, Shantsila, E, Lip, G Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009; 373(9658):155–66.
Manning, W J, et al. Impaired left atrial mechanical function after cardioversion: Relation to the duration of atrial fibrillation. J Am Coll Cardiol. 1994; 23(7):1535–40.
O’Neill, P G, et al. Return of atrial mechanical function following electrical conversion of atrial dysrhythmias. Am Heart J. 1990; 120(2):353–9.
Shapiro, E P, et al. Transient atrial dysfunction after conversion of chronic atrial fibrillation to sinus rhythm. Am J Cardiol. 1988; 62(17):1202–7.
Ikram, H, Nixon, PG, Arcan, T. Left atrial function after electrical conversion to sinus rhythm. Br Heart J. 1968; 30(1):80–3.
Manning, W J, et al. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol. 1989; 13(3):617–23.
Grimm, R A, et al. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: Characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol. 1993; 22(5):1359–66.
Black, I W, et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation. 1994; 89(6):2509–13.
Black, I W, et al. Evaluation of transesophageal echocardiography before cardioversion of atrial fibrillation and flutter in nonanticoagulated patients. Am Heart J. 1993; 126(2):375–81.
Missault, L, et al. Embolic stroke after unanticoagulated cardioversion despite prior exclusion of atrial thrombi by transoesophageal echocardiography. Eur Heart J. 1994; 15(9):1279–80.
Bjerkelund, C J, Orning, O M. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol. 1969; 23(2):208–16.
Lown, B. Electrical reversion of cardiac arrhythmias. Br Heart J. 1967; 29(4):469–89.
Oram, S, Davies, J P. Further experience of electrical conversion of atrial fibrillation to sinus rhythm: Analysis of 100 patients. Lancet. 1964; 1(7346):1294–8.
Resnekov, L, McDonald, L. Complications in 220 patients with cardiac dysrhythmias treated by phased direct current shock, and indications for electroconversion. Br Heart J. 1967; 29(6):926–36.
McCarthy, C, Varghese, P J, Barritt, D W. Prognosis of atrial arrhythmias treated by electrical counter shock therapy. A three-year follow-up. Br Heart J. 1969; 31(4):496–500.
Berger, M, Schweitzer, P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: A retrospective analysis. Am J Cardiol. 1998; 82(12):1545–7.
Gallagher, M M, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: Association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol. 2002; 40(5):926–33.
Arnold, A Z, et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol. 1992; 19(4):851–5.
Collins, L J, et al. Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation. 1995; 92(2):160–3.
Israel, C W, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol. 2004; 43(1):47–52.
Camm, A J, et al. focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33(21):2719–47.
Camm, A J, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31(19):2369–429.
www.uptodate.com/contents/warfarin-drug-information?source=see_link. [Accessed September 27, 2015].
Connolly, S J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139–51.
www.uptodate.com/contents/warfarin-drug-information?source=see_link. [Accessed September 27, 2015].
Nagarakanti, R, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011; 123(2):131–6.
www.uptodate.com/contents/warfarin-drug-information?source=see_link. [Accessed on September 27, 2015].
www.uptodate.com/contents/warfarin-drug-information?source=see_link. [Accessed September 27, 2015].
Granger, C B, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981–92.
Flaker, G, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: Insights from the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation). Journal of the American College of Cardiology. 2014; 63:1082–7.
Patel, M R, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–91.
Cappato, R, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. European Heart Journal. 2014; 35:3346–55.
www.uptodate.com/contents/warfarin-drug-information?source=see_link. [Accessed September 27, 2015].
Weigner, M J, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997; 126:615–20.
Stoddard, M F, et al. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J. 1995; 129(6):1204–15.
Stoddard, M F, et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographic study. J Am Coll Cardiol. 1995; 25(2):452–9.
Klein, A L, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med. 2001; 344(19):1411–20.
Weigner, M J, et al. Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: Short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med. 2001; 110(9):694–702.
Camm, A J, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010; 12(10):1360–420.
www.uptodate.com/contents/warfarin-drug-information?source=see_link. [Accessed September 27, 2015].
References
Tisdale, J E, Miller, D A. American Society of Health-System Pharmacists. Drug-induced Diseases: Prevention, Detection, and Management. Bethesda, MD: American Society of Health-System Pharmacists; 2005.
Flaherty, M L. Anticoagulant-associated intracerebral hemorrhage. Seminars in Neurology. 2010; 30:565–72.
Cantu, C, Arauz, A, Murillo-Bonilla, L M, Lopez, M, Barinagarrementeria, F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke. 2003; 34:1667–72.
Jain, K K. Drug-induced Neurological Disorders. Cambridge, MA: Hogrefe Pub; 2012.
Plu-Bureau, G, Hugon-Rodin, J, Maitrot-Mantelet, L, Canonico, M. Hormonal contraceptives and arterial disease: An epidemiological update. Best Practice & Research. Clinical Endocrinology & Metabolism. 2013; 27:35–45.
Plu-Bureau, G, Maitrot-Mantelet, L, Hugon-Rodin, J, Canonico, M. Hormonal contraceptives and venous thromboembolism: An epidemiological update. Best Practice & Research. Clinical Endocrinology & Metabolism. 2013; 27:25–34.
Godsland, I F, Winkler, U, Lidegaard, O, Crook, D. Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms. Drugs. 2000; 60:721–869.
Meade, T W, Greenberg, G, Thompson, S G. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations. British Medical Journal. 1980; 280:1157–61.
Lidegaard, O. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: The influence of diabetes, hypertension, migraine and previous thrombotic disease. British Journal of Obstetrics and Gynaecology. 1995; 102:153–9.
Lidegaard, O, Kreiner, S. Contraceptives and cerebral thrombosis: A five-year national case-control study. Contraception. 2002; 65:197–205.
Chan, W S, Ray, J, Wai, E K, et al. Risk of stroke in women exposed to low-dose oral contraceptives: A critical evaluation of the evidence. Archives of Internal Medicine. 2004; 164:741–7.
Schurks, M, Rist, P M, Bigal, M E, et al. Migraine and cardiovascular disease: Systematic review and meta-analysis. British Medical Journal. 2009; 339:b3914.
Saposnik, G, Barinagarrementeria, F, Brown, R D Jr., et al. Diagnosis and management of cerebral venous thrombosis: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42:1158–92.
Saadatnia, M, Naghavi, N, Fatehi, F, Zare, M, Tajmirriahi, M. Oral contraceptive misuse as a risk factor for cerebral venous and sinus thrombosis. Journal of Research in Medical Sciences. 2012; 17:344–7.
Ashjazadeh, N, Borhani Haghighi, A, Poursadeghfard, M, Azin, H. Cerebral venous-sinus thrombosis: A case series analysis. Iranian Journal of Medical Sciences. 2011; 36:178–82.
Martinelli, I, Sacchi, E, Landi, G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. New England Journal of Medicine. 1998; 338:1793–7.
de Bruijn, S F, Stam, J, Koopman, M M, Vandenbroucke, J P. The Cerebral Venous Sinus Thrombosis Study Group. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. British Medical Journal. 1998; 316:589–92.
Dentali, F, Crowther, M, Ageno, W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: A meta-analysis. Blood. 2006; 107:2766–73.
Dunne, C, Malyuk, D, Firoz, T. Cerebral venous sinus thrombosis in a woman using the etonogestrel-ethinyl estradiol vaginal contraceptive ring: A case report. Journal of Obstetrics and Gynaecology Canada. 2010; 32:270–3.
Shetty, K D, Vogt, W B, Bhattacharya, J. Hormone replacement therapy and cardiovascular health in the United States. Medical Care. 2009; 47:600–6.
Rossouw, J E, Anderson, G L, Prentice, R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. Journal of the American Medical Association. 2002; 288:321–33.
Wassertheil-Smoller, S, Hendrix, S L, Limacher, M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The women’s health initiative: A randomized trial. Journal of the American Medical Association. 2003; 289:2673–84.
Ruige, J B, Mahmoud, A M, De Bacquer, D, Kaufman, J M. Endogenous testosterone and cardiovascular disease in healthy men: A meta-analysis. Heart. 2011; 97:870–5.
Yeap, B B, Hyde, Z, Almeida, O P, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. Journal of Clinical Endocrinology and Metabolism. 2009; 94:2353–9.
Ferenchick, G, Schwartz, D, Ball, M, Schwartz, K. Androgenic-anabolic steroid abuse and platelet aggregation: A pilot study in weight lifters. American Journal of the Medical Sciences. 1992; 303:78–82.
Stergiopoulos, K, Brennan, J J, Mathews, R, Setaro, J F, Kort, S. Anabolic steroids, acute myocardial infarction and polycythemia: A case report and review of the literature. Vascular Health and Risk Management. 2008; 4:1475–80.
Warkentin, T E, Greinacher, A, Koster, A, Lincoff, A M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133:340S–380S.
Linkins, L A, Dans, A L, Moores, L K, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141:e495S–530S.
Visentin, G P, Ford, S E, Scott, J P, Aster, R H. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. Journal of Clinical Investigation. 1994; 93:81–8.
Newman, P M, Chong, B H. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-pf4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000; 96:182–7.
Giossi, A, Del Zotto, E, Volonghi, I, et al. Thromboembolic complications of heparin-induced thrombocytopenia. Blood Coagulation & Fibrinolysis. 2012; 23:559–62.
LaMonte, M P, Brown, P M, Hursting, M J. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Critical Care Medicine. 2004; 32:976–80.
Li, S H, Chen, W H, Tang, Y, et al. Incidence of ischemic stroke post-chemotherapy: A retrospective review of 10,963 patients. Clinical Neurology and Neurosurgery. 2006; 108:150–6.
Czaykowski, P M, Moore, M J, Tannock, I F. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. Journal of Urology. 1998; 160:2021–4.
Wall, J G, Weiss, R B, Norton, L, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: A cancer and leukemia group B study. American Journal of Medicine. 1989; 87:501–4.
Bachaud, J M, David, J M, Shubinski, R E, et al. Predictive factors of a complete response to and adverse effects of a cddp-5fu combination as primary therapy for head and neck squamous carcinomas. Journal of Laryngology and Otology. 1993; 107:924–30.
Skali, H, Parving, H H, Parfrey, P S, et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: The trial to reduce cardiovascular events with aranesp therapy (treat) experience. Circulation. 2011; 124:2903–8.
Pfeffer, M A, Burdmann, E A, Chen, C Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine. 2009; 361:2019–32.
FDA Drug Safety Communication. Erythropoiesis-stimulating agents (ESAS): Procrit, epogen and aranesp. 2010.
FDA Drug Safety Communication. Modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAS) in chronic kidney disease. 2011.
Ehrenreich, H, Weissenborn, K, Prange, H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009; 40:e647–656.
Fergusson, D A, Hebert, P C, Mazer, C D, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. New England Journal of Medicine. 2008; 358:2319–31.
Mangano, D T, Tudor, I C, Dietzel, C. The risk associated with aprotinin in cardiac surgery. New England Journal of Medicine. 2006; 354:353–65.
Roberts, I, Perel, P, Prieto-Merino, D, et al. Effect of tranexamic acid on mortality in patients with traumatic bleeding: Prespecified analysis of data from randomised controlled trial. British Medical Journal. 2012; 345:e5839.
Roos, Y B, Rinkel, G J, Vermeulen, M, Algra, A, van Gijn, J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database of Systematic Reviews. 2003: CD001245.
Idbaih, A, Crassard, I, Vahedi, K, Guichard, J P, Woimant, F. Thrombotic cocktail in stroke. Neurology. 2005; 64:334.
Brown, J E, Olujohungbe, A, Chang, J, et al. All-trans retinoic acid (ATRA) and tranexamic acid: A potentially fatal combination in acute promyelocytic leukaemia. British Journal of Haematology. 2000; 110:1010–12.
Caress, J B, Cartwright, M S, Donofrio, P D, Peacock, J E Jr. The clinical features of 16 cases of stroke associated with administration of IVIG. Neurology. 2003; 60:1822–4.
Katz, U, Shoenfeld, Y. Review: Intravenous immunoglobulin therapy and thromboembolic complications. Lupus. 2005; 14:802–8.
Orbach, H, Katz, U, Sherer, Y, Shoenfeld, Y. Intravenous immunoglobulin: Adverse effects and safe administration. Clinical Reviews in Allergy & Immunology. 2005; 29:173–84.
Caress, J B, Hobson-Webb, L, Passmore, L V, Finkbiner, A P, Cartwright, M S. Case-control study of thromboembolic events associated with IV immunoglobulin. Journal of Neurology. 2009; 256:339–42.
Haag, M D, Bos, M J, Hofman, A, et al. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Archives of Internal Medicine. 2008; 168:1219–24.
Roumie, C L, Mitchel, E F Jr., Kaltenbach, L, et al. Nonaspirin NSAIDS, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke. 2008; 39:2037–45.
Andersohn, F, Schade, R, Suissa, S, Garbe, E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: A nested case-control study. Stroke. 2006; 37:1725–30.
Fosbol, E L, Olsen, A M, Olesen, J B, et al. Use of nonsteroidal anti-inflammatory drugs among healthy people and specific cerebrovascular safety. International Journal of Stroke. 2012; 9:943–5.
Chang, C H, Shau, W Y, Kuo, C W, Chen, S T, Lai, M S. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: A nationwide case-crossover study. Stroke. 2010; 41:1884–90.
Bennett, J S, Daugherty, A, Herrington, D, et al. The use of nonsteroidal anti-inflammatory drugs (NSAIDS): A science advisory from the American Heart Association. Circulation. 2005; 111:1713–16.
Antman, E M, Bennett, J S, Daugherty, A, et al. Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association. Circulation. 2007; 115:1634–42.
Sklar, P, Masur, H. HIV infection and cardiovascular disease: Is there really a link? New England Journal of Medicine. 2003; 349:2065–7.
Engstrom, J W, Lowenstein, D H, Bredesen, D E. Cerebral infarctions and transient neurologic deficits associated with acquired immunodeficiency syndrome. American Journal of Medicine. 1989; 86:528–32.
Qureshi, A I, Janssen, R S, Karon, J M, et al. Human immunodeficiency virus infection and stroke in young patients. Archives of Neurology. 1997; 54:1150–3.
Mochan, A, Modi, M, Modi, G. Protein S deficiency in HIV associated ischaemic stroke: An epiphenomenon of HIV infection. Journal of Neurology, Neurosurgery, and Psychiatry. 2005; 76:1455–6.
Qureshi, A I. HIV infection and stroke: If not protein S deficiency then what explains the relationship? Journal of Neurology, Neurosurgery, and Psychiatry. 2005; 76:1331.
Vaughn, G, Detels, R. Protease inhibitors and cardiovascular disease: Analysis of the Los Angeles County Adult Spectrum of Disease cohort. AIDS Care. 2007; 19:492–9.
Monsuez, J J, Goujon, C, Wyplosz, B, et al. Cerebrovascular diseases in HIV-infected patients. Current HIV Research. 2009; 7:475–80.
Corral, I, Quereda, C, Moreno, A, et al. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: Incidence and risk factors. Cerebrovascular Diseases. 2009; 27:559–63.
Ortiz, G, Koch, S, Romano, J G, Forteza, A M, Rabinstein, A A. Mechanisms of ischemic stroke in HIV-infected patients. Neurology. 2007; 68:1257–61.
Mangili, A, Gerrior, J, Tang, A M, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: A study using carotid intima-media thickness and coronary artery calcium score. Clinical Infectious Diseases. 2006; 43:1482–9.
Sen, S, Rabinstein, A A, Elkind, M S, Powers, W J. Recent developments regarding human immunodeficiency virus infection and stroke. Cerebrovascular Diseases. 2012; 33:209–18.
Dobbs, M R, Berger, J R. Stroke in HIV infection and AIDS. Expert Review of Cardiovascular Therapy. 2009; 7:1263–71.
Chen, S P, Fuh, J L, Wang, S J. Reversible cerebral vasoconstriction syndrome: Current and future perspectives. Expert Review of Neurotherapeutics. 2011; 11:1265–76.
Salvarani, C, Brown, R D Jr., Hunder, G G. Adult primary central nervous system vasculitis. Lancet. 2012; 380:767–77.
Calabrese, L H, Duna, G F. Drug-induced vasculitis. Current Opinion in Rheumatology. 1996; 8:34–40.
Citron, B P, Halpern, M, McCarron, M, et al. Necrotizing angiitis associated with drug abuse. New England Journal of Medicine. 1970; 283:1003–11.
Lim, D, Rademaker, M, Asztely, F, Ratnaweera, M, Coltman, G. Cerebral vasculitis and multi-focal neurological deficits due to allopurinol-induced hypersensitivity syndrome. Australasian Journal of Dermatology. 2013.
Rothwell, P M, Grant, R. Cerebral vasculitis following allopurinol treatment. Postgraduate Medical Journal. 1996; 72:119–20.
Flaherty, M L, Kissela, B, Woo, D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007; 68:116–21.
Whitlock, R P, Sun, J C, Fremes, S E, Rubens, F D, Teoh, K H. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141:e576S–600S.
You, J J, Singer, D E, Howard, P A, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141:e531S–575S.
Ageno, W, Gallus, A S, Wittkowsky, A, et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141:e44S–88S.
Hylek, E M, Skates, S J, Sheehan, M A, Singer, D E. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. New England Journal of Medicine. 1996; 335:540–6.
Hart, R G, Boop, B S, Anderson, D C. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995; 26:1471–7.
Fang, M C, Go, A S, Chang, Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. American Journal of Medicine. 2007; 120:700–5.
Quinones-Hinojosa, A, Gulati, M, Singh, V, Lawton, M T. Spontaneous intracerebral hemorrhage due to coagulation disorders. Neurosurgical Focus. 2003; 15:E3.
Hampton, K K, Preston, F E. ABC of clinical haematology. Bleeding disorders, thrombosis, and anticoagulation. British Medical Journal. 1997; 314:1026–9.
Vernooij, M W, Haag, M D, van der Lugt, A, et al. Use of antithrombotic drugs and the presence of cerebral microbleeds: The Rotterdam scan study. Archives of Neurology. 2009; 66:714–20.
Thompson, B B, Bejot, Y, Caso, V, et al. Prior antiplatelet therapy and outcome following intracerebral hemorrhage: A systematic review. Neurology. 2010; 75:1333–42.
Naidech, A M, Bendok, B R, Garg, R K, et al. Reduced platelet activity is associated with more intraventricular hemorrhage. Neurosurgery. 2009; 65:684–8.
He, J, Whelton, P K, Vu, B, Klag, M J. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials. Journal of the American Medical Association. 1998; 280:1930–5.
Foerch, C, Sitzer, M, Steinmetz, H, Neumann-Haefelin, T. Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke. 2006; 37:2165–7.
Toyoda, K, Okada, Y, Minematsu, K, et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology. 2005; 65:1000–4.
Toyoda, K, Yasaka, M, Nagata, K, et al. Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage. The bleeding with antithrombotic therapy (BAT) retrospective study. Cerebrovascular Diseases. 2009; 27:151–9.
Saloheimo, P, Ahonen, M, Juvela, S, et al. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke. 2006; 37:129–33.
Creutzfeldt, C J, Weinstein, J R, Longstreth, W T Jr., et al. Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage. Journal of Stroke & Cerebrovascular Diseases. 2009; 18:221–8.
Caso, V, Paciaroni, M, Venti, M, et al. Effect of on-admission antiplatelet treatment on patients with cerebral hemorrhage. Cerebrovascular Diseases. 2007; 24:215–18.
Roquer, J, Rodriguez Campello, A, Gomis, M, et al. Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage. Journal of Neurology. 2005; 252:412–16.
Lacut, K, Le Gal, G, Seizeur, R, et al. Antiplatelet drug use preceding the onset of intracerebral hemorrhage is associated with increased mortality. Fundamental & Clinical Pharmacology. 2007; 21:327–33.
Hanger, H C, Fletcher, V J, Wilkinson, T J, et al. Effect of aspirin and warfarin on early survival after intracerebral haemorrhage. Journal of Neurology. 2008; 255:347–52.
Sansing, L H, Messe, S R, Cucchiara, B L, et al. Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology. 2009; 72:1397–402.
Moussouttas, M, Malhotra, R, Fernandez, L, et al. Role of antiplatelet agents in hematoma expansion during the acute period of intracerebral hemorrhage. Neurocritical Care. 2010; 12:24–9.
Stead, L G, Jain, A, Bellolio, M F, et al. Effect of anticoagulant and antiplatelet therapy in patients with spontaneous intra-cerebral hemorrhage: Does medication use predict worse outcome? Clinical Neurology & Neurosurgery. 2010; 112:275–81.
Ishibashi, A, Yokokura, Y, Adachi, H. Is antiplatelet therapy for the prevention of ischemic stroke associated with the prognosis of intracerebral hemorrhage? Kurume Medical Journal. 2008; 55:71–5.
Nicolini, A, Ghirarduzzi, A, Iorio, A, et al. Intracranial bleeding: Epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. Haematologica. 2002; 87:948–56.
Baldi, G, Altomonte, F, Altomonte, M, et al. Intracranial haemorrhage in patients on antithrombotics: Clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. Cerebrovascular Diseases. 2006; 22:286–93.
Lovelock, C E, Cordonnier, C, Naka, H, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: A systematic review of published and unpublished studies. Stroke. 2010; 41:1222–8.
Naidech, A M, Bernstein, R A, Levasseur, K, et al. Platelet activity and outcome after intracerebral hemorrhage. Annals of Neurology. 2009; 65:352–6.
Naidech, A M, Jovanovic, B, Liebling, S, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke. 2009; 40:2398–401.
de Gans, K, de Haan, R J, Majoie, C B, et al. PATCH: Platelet Transfusion in Cerebral Haemorrhage: Study protocol for a multicentre, randomised, controlled trial. BMC Neurology. 2010; 10:19.
Memon, M A, Blankenship, J C, Wood, G C, Frey, C M, Menapace, F J. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis of major clinical trials. American Journal of Medicine. 2000; 109:213–17.
Qureshi, A I, Suri, M F, Ali, Z, et al. Carotid angioplasty and stent placement: A prospective analysis of perioperative complications and impact of intravenously administered abciximab. Neurosurgery. 2002; 50:466–73.
Qureshi, A I, Saad, M, Zaidat, O O, et al. Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab. Stroke. 2002; 33:1916–19.
Adams, H P Jr., Effron, M B, Torner, J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial: Abciximab in emergency treatment of stroke trial (ABESTT-II). Stroke. 2008; 39:87–99.
Adams, H P Jr., Leira, E C, Torner, J C, et al. Treating patients with “wake-up” stroke: The experience of the ABESTT-II trial. Stroke. 2008; 39:3277–82.
Hirsh, J, Guyatt, G, Albers, G W, Harrington, R, Schunemann, H J, American College of Chest Physicians. Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133:110S–112S.
The National Institute of Neurological Disorders and Stroke RT-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine. 1995; 333:1581–7.
Strbian, D, Sairanen, T, Meretoja, A, et al. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology. 2011; 77:341–8.
Herrmann, N, Lanctot, K L. Do atypical antipsychotics cause stroke? CNS Drugs. 2005; 19:91–103.
Sacchetti, E, Turrina, C, Valsecchi, P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: A systematic review. Drug Safety. 2010; 33:273–88.
Christensen, S, Mehnert, F, Chapurlat, R D, Baron, J A, Sorensen, H T. Oral bisphosphonates and risk of ischemic stroke: A case-control study. Osteoporosis International. 2011; 22:1773–9.
Wilkinson, G S, Baillargeon, J, Kuo, Y F, Freeman, J L, Goodwin, J S. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. Journal of Clinical Oncology. 2010; 28:4898–905.
Gallagher, A M, Smeeth, L, Seabroke, S, Leufkens, H G, van Staa, T P. Risk of death and cardiovascular outcomes with thiazolidinediones: A study with the general practice research database and secondary care data. PloS One. 2011; 6:e28157.
Panicker, G K, Karnad, D R, Salvi, V, Kothari, S. Cardiovascular risk of oral antidiabetic drugs: Current evidence and regulatory requirements for new drugs. J Assoc Physicians India. 2012; 60:56–61.
Morgenstern, L B, Hemphill, J C 3rd, Anderson, C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010; 41:2108–29.
Jauch, E C, Saver, J L, Adams, H P Jr. et al. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44:870–947.
Ducros, A, Bousser, M G. Reversible cerebral vasoconstriction syndrome. Practical Neurology. 2009; 9:256–67.
Mittal, M K, Rabinstein, A A. Anticoagulation-related intracranial hemorrhages. Current Atherosclerosis Reports. 2012; 14:351–9.
Hirsh, J, Anand, S S, Halperin, J L, Fuster, V. Mechanism of action and pharmacology of unfractionated heparin. Arteriosclerosis, Thrombosis, and Vascular Biology. 2001; 21:1094–6.
Choay, J, Petitou, M, Lormeau, JC, et al. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochemical and Biophysical Research Communications. 1983; 116:492–9.
Crowther, M A, Warkentin, T E. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: Focus on new anticoagulant agents. Blood. 2008; 111:4871–9.
Watanabe, M, Siddiqui, F M, Qureshi, A I. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocritical Care. 2012; 16:203–9.
Baz, R, Mekhail, T. Disorders of platelet function and number. 2010.
Konkle, B A. Acquired disorders of platelet function. ASH Education Program Book. 2011; 391–6.
Kenney, B, Stack, G. Drug-induced thrombocytopenia. Archives of Pathology and Laboratory Medicine. 2009; 133:309–14.
Steiner, T, Poli, S, Griebe, M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage (INCH): a randomized trial. Lancet. 2016; 15:566–73.
Pollack, C V, Reilly, P A, Eikelboom, J, et al. Idarucizamab for dibigatran reversal. New England Journal of Medicine. 2015; 373:511–20.